By Ben Glickman
Catalyst Pharmaceuticals said that it would commercially launch Agamree, a treatment for Duchenne Muscular Dystrophy, after the treatment was approved by the U.S. Food and Drug Administration.
Catalyst holds the exclusive North American license to commercialize Agamree, which was developed by Santhera Pharmaceuticals. Catalyst…
Read the full article here